Although these experiments show that HRG/ErbB3 signaling has the ability to render ovarian cancer cells insensitive to paclitaxel, the question remains whether or not cancer cells invoke this mechanism to adapt to the stress of cytotoxic therapy. This evidence concerns the gene HRG and cancer.